Welcome to our dedicated page for Simulations Plus news (Ticker: SLP), a resource for investors and traders seeking the latest updates and insights on Simulations Plus stock.
Simulations Plus, Inc. (Nasdaq: SLP) is frequently in the news for developments at the intersection of biosimulation software, cheminformatics, and AI‑enabled drug development. Company press releases cover its role as a global leader in model‑informed and AI‑accelerated drug development, highlighting how its software and services support pharmaceutical and biotechnology organizations throughout the drug lifecycle.
News items commonly include quarterly and annual financial results, where Simulations Plus reports revenue contributions from its software and services segments, discusses demand trends, and provides guidance ranges for future periods. Management commentary often addresses bookings in software and services, adoption of cloud deployment and AI‑driven workflows, and the impact of market conditions on client spending.
Investors following SLP news will also see announcements about product strategy and AI initiatives, such as the company’s integrated, AI‑enabled modeling ecosystem connecting platforms like GastroPlus®, MonolixSuite®, ADMET Predictor®, and QSP/QST tools. Releases describe cloud‑scale compute, AI copilots that guide complex modeling workflows, and an AI‑orchestrated framework designed to support multi‑engine simulations and decision support.
The company’s news flow includes scientific and collaboration updates, for example validation of AI‑driven drug design in ADMET Predictor® through collaborations and published case studies, and commentary on alignment with regulatory guidance for model‑informed nonclinical safety assessments. Additional items cover investor events such as conference presentations and virtual Investor Day sessions that provide detail on long‑term strategy, product roadmaps, and financial outlook.
By monitoring the SLP news page, readers can track how Simulations Plus communicates its financial performance, advances in biosimulation and AI, regulatory‑aligned modeling capabilities, and strategic initiatives within the biopharma technology landscape.
Simulations Plus, Inc. (Nasdaq: SLP) reported a 13% increase in total revenue for Q2 FY2022, reaching $14.8 million. Software revenue grew by 25% to $9.8 million, now comprising 66% of total revenue. The company’s diluted EPS rose 40% to $0.21, with net income at $4.4 million.
Despite a 5% decline in services revenue, strong performance in the software sector, particularly MonolixSuite®, which saw 43% growth, boosted overall results. The Board declared a quarterly dividend of $0.06 per share.
Simulations Plus (SLP) has announced a partnership with the University of Pittsburgh to develop and validate its BIOLOGXsym™ platform, focused on quantitative systems toxicology for liver safety. A Phase II SBIR NIH grant of approximately $1.7 million will fund software development and lab work over two years. The collaboration aims to enhance drug safety assessments, particularly for large molecules, and will utilize the university's advanced organ-on-a-chip technology for testing. This initiative is seen as a pivotal step in expanding SLP's offerings in the growing therapeutic development market.
Simulations Plus (NASDAQ: SLP) announced record attendance for the 2022 MIDD+ Scientific Conference held on February 16-17, attracting participants from 57 countries. The event focused on advancing model-informed drug development with sessions covering all drug development stages. Keynote speaker Rajanikanth Madabushi from the FDA emphasized a holistic approach. Presentations included regulatory perspectives from global agencies. The conference highlights the company's leadership in biosimulation and its role in the pharmaceutical industry.
Simulations Plus (NASDAQ: SLP) announced it will report its financial results for the second quarter of fiscal year 2022 on April 6, 2022, after market close. The announcement includes a conference call scheduled for 5:00 PM ET on the same day, where stakeholders can join via registration link or phone. The company provides advanced biosimulation software and consulting services for drug discovery, and has been in operation for 25 years, serving clients globally.
Summary not available.
Simulations Plus (NASDAQ: SLP) has launched MembranePlus™ 3.0, enhancing in vitro-in vivo extrapolation (IVIVE) for transdermal product analysis. Key features include new models for in vitro penetration and release tests, expanded membrane transport parameters, and improved simulation performance. The update aims to provide insights for formulation strategies, reducing the need for animal testing. Senior Scientist Dr. Jessica Spires noted the product's integration with GastroPlus® to benefit researchers in predicting topical administration outcomes.
Simulations Plus (Nasdaq: SLP) announced its participation in Oppenheimer’s 32nd Annual Healthcare Conference, occurring virtually on March 15-16, 2022. CEO Shawn O’Connor will present on March 15 at 4:00 p.m. ET and will also host one-on-one meetings. Interested parties can access the live event or request meetings via their Oppenheimer representatives. The presentation slides will be available afterwards on the company’s Investors page.
Simulations Plus, serving clients for 25 years, specializes in modeling and simulation software for pharmaceutical development and research.
Simulations Plus, a leader in biosimulation software, will present at the Raymond James 43rd Annual Institutional Investors Conference from March 6-9, 2022, in Orlando, Florida. CEO Shawn O’Connor is scheduled to present on March 9 at 10:25 a.m. ET and will conduct one-on-one meetings. Attendance is by invitation only. The presentation will be available on the Simulations Plus Investors page. This conference is a key event for engaging with institutional investors and showcasing advancements in pharmaceutical modeling and simulation.
Simulations Plus (Nasdaq: SLP), a key player in biosimulation software for pharmaceuticals, announced participation in BTIG's MedTech, Digital Health, Life Science and Diagnostic Tools Conference from February 15-17, 2022. CEO Shawn O'Connor will present on February 15 at 3:30 p.m. ET and will be available for one-on-one meetings. Interested parties can view the slide presentation on the investors page post-presentation. For more details on the event, visit BTIG's website.
Simulations Plus (NASDAQ: SLP) announced a new collaboration with a large pharmaceutical company to enhance its GastroPlus® ACAT™ model for better understanding of drug disposition in the gastrointestinal tract. The partnership aims to improve functionalities related to local gut delivery and bolster data handling for drug evaluation. This initiative reflects the company's commitment to advancing drug development processes and solidifying its position in biosimulation.